Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
NCT06113081 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-12-24
Summary
This study is designed to describe the clinical activity and safety profile of mogamulizumab at standard dose in the treatment of CTCL patients in real world setting
Conditions
- Cutaneous T Cell Lymphoma
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Cutaneous T-Cell Lymphoma/Sezary Syndrome
Sponsors & Collaborators
-
Fondazione Italiana Linfomi - ETS
lead OTHER
Principal Investigators
-
Pietro Quaglino, MD · SC Dermatologia U - A.O.U. Città della Salute e della Scienza di Torino
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-06-06
- Primary Completion
- 2025-10-10
- Completion
- 2025-11-11
Countries
- Italy
Study Locations
More Related Trials
-
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
NCT06008691 ·Status: RECRUITING
-
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
NCT05406154 ·Status: UNKNOWN
-
Relmacabtagene Autoleucel in Hematologic Malignancies
NCT06142188 ·Status: NOT_YET_RECRUITING
-
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
NCT07058103 ·Status: RECRUITING ·Phase: PHASE2
-
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
NCT04433182 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Acalabrutinib and Tafasitamab in MZL Patients
NCT04646395 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
NCT06436677 ·Status: RECRUITING
-
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05189782 ·Status: UNKNOWN
-
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
NCT02682641 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
NCT05977673 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas
NCT02597153 ·Status: TERMINATED ·Phase: PHASE2
-
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
NCT05590221 ·Status: RECRUITING ·Phase: PHASE2
-
CTCL Directed Therapy
NCT03116659 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06693973 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Long-term Use of Romidepsin in Patients With CTCL
NCT02296398 ·Status: COMPLETED
-
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
NCT00656812 ·Status: COMPLETED ·Phase: PHASE2
-
Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma
NCT05486013 ·Status: RECRUITING
-
Diagnostic Classifier for Cutaneous T-cell Lymphomas
NCT04491825 ·Status: UNKNOWN
-
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
NCT04101331 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT03209973 ·Status: COMPLETED ·Phase: PHASE2
-
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
NCT05557903 ·Status: UNKNOWN ·Phase: PHASE1
-
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT01880567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT03206970 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT01647971 ·Status: COMPLETED ·Phase: PHASE1/PHASE2